Please login to the form below

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance. 

There’s no doubt that the cheaper cost of biosimilars versus their originator biologic, even though not as substantial as generics, make them very attractive to healthcare markets. But so far, biosimilar manufacturers have dedicated most of their efforts to convincing payers of these cost benefits, seeing them as the primary gatekeeper of market access. However, by focusing just on payers, are they missing a trick? In the longer-term, manufacturers could benefit from educating and winning over a wider audience, and not just physicians, but also patients...

http://www.researchpartnership.com/news/2016/09/article-biosimilars-bringing-patients-into-the-conve...


25th January 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Article
How will COVID-19 affect uptake of vaccinations against other diseases?
Research Partnership
Podcast
Living With Chronic Illness (Series one)
Research Partnership
Live webinar
China: How pharma can maximize success in this rapidly changing emerging market
Research Partnership
Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership
Infographic
Migraine market snapshot
Research Partnership
Webinar
Monitoring the impact of COVID-19 on the market access landscape
Research Partnership